Abstract
Targeted antibody therapy represents a promising approach for the treatment of cancer. However, antibodies that bind to cancer cells are often, by themselves, not cytotoxic. Recombinant immunotoxins (RITs) are chimeric proteins composed of the variable fragment (Fv) of a monoclonal antibody fused to a portion of a powerful bacterial toxin. The Fv replaces the cell-binding domain of the toxin and directs the toxin to cancer cells that express an internalizing target antigen. RITs are very potent and are able to kill cells that are resistant to standard chemotherapy. Results from clinical trials indicate that RITs that are designed to combine antibody selectivity with toxin cell-killing potency will be useful additions to cancer therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Brinkmann U, Reiter Y, Jung S-H, Lee B, Pastan I (1993) A recombinant immunotoxin containing a disulfide-stabilized Fv fragment (dsFv). Proc Natl Acad Sci USA 90:7538–7542
Hassan R, Bullock S, Premkumar A et al (2007) Phase I study of SS1P, a recombinant antimesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelinexpressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13:5144–5149
Ho M, Kreitman RJ, Onda M, Pastan I (2005) In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem 280:607–617
Hwang J, FitzGerald DJP, Adhya S, Pastan I (1987) Functional domains of pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell 48:129–136
Kreitman RJ, Wilson WH, White JD et al (2000) Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18:1622–1636
Kreitman RJ, Wilson WH, Bergeron K et al (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345:241–247
Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6:559–565
Studier FW, Moffatt BA (1986) Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol 189:113–130
Acknowledgement
This research was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.
Portions of the manuscript have been previously published in: Pastan I, Beers R, and Bera TK (2003) Recombinant immunotoxins in the treatment of cancer. Lo BKC (ed) Methods in molecular biology, vol 248. Antibody engineering methods and protocols, New Jersey, Humana Press, pp 503–518
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this protocol
Cite this protocol
Pastan, I., Ho, M. (2010). Recombinant Immunotoxins for Treating Cancer. In: Kontermann, R., Dübel, S. (eds) Antibody Engineering. Springer Protocols Handbooks. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01147-4_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-01147-4_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-01146-7
Online ISBN: 978-3-642-01147-4
eBook Packages: Springer Protocols